{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:48:27Z","timestamp":1787021307902,"version":"build-2736575974"},"reference-count":18,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Teprotumumab, an insulin-like growth factor-1 (IGF-1) receptor antibody, has been approved for thyroid eye disease (TED) treatment. However, teprotumumab is associated with adverse events such as hyperglycemia, and the underlying mechanisms of teprotumumab-related hyperglycemia remain unclear. We report a case of teprotumumab-related hyperglycemia with endocrinological evaluation. A 60-year-old woman with Graves disease developed active TED and was treated with teprotumumab. The patient had preexisting type 2 diabetes managed with oral hypoglycemic agents. At 6 weeks after teprotumumab initiation, glycemic control deteriorated, necessitating temporary teprotumumab discontinuation and insulin therapy initiation. Serum growth hormone (GH) level changed minimally, whereas serum IGF-1 level increased markedly, suggesting increased integrated GH secretion. Fasting plasma glucose level substantially increased, whereas serum immunoreactive insulin level only modestly increased, indicating insufficient endogenous insulin secretion. Following glycemic improvement with insulin therapy, teprotumumab was resumed, and 8 infusions were completed. Despite persistently elevated serum IGF-1 levels, insulin was gradually tapered with concomitant weight loss and was discontinued at 9 weeks after the final infusion. In patients with reduced endogenous insulin secretory capacity, teprotumumab-related hyperglycemia may develop when endogenous insulin secretion is insufficient to compensate for GH-mediated increases in hepatic gluconeogenesis and insulin resistance.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag186","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:03:10Z","timestamp":1783904590000},"source":"Crossref","is-referenced-by-count":1,"title":["Thyroid eye disease with teprotumumab-related hyperglycemia associated with increased growth hormone secretion"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6247-9500","authenticated-orcid":false,"given":"Ken","family":"Sugawa","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kobe City Medical Center General Hospital , Kobe, Hyogo 650-0047 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4710-6393","authenticated-orcid":false,"given":"Yuji","family":"Hataya","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kobe City Medical Center General Hospital , Kobe, Hyogo 650-0047 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Murabe","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kobe City Medical Center General Hospital , Kobe, Hyogo 650-0047 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-4055","authenticated-orcid":false,"given":"Kanta","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kobe City Medical Center General Hospital , Kobe, Hyogo 650-0047 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Iwakura","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kobe City Medical Center General Hospital , Kobe, Hyogo 650-0047 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-1487","authenticated-orcid":false,"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kobe City Medical Center General Hospital , Kobe, Hyogo 650-0047 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"1","key":"2026071221004507300_luag186-B1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"issue":"18","key":"2026071221004507300_luag186-B2","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026071221004507300_luag186-B3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071221004507300_luag186-B4","article-title":"Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review","volume":"16","author":"Xu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2026071221004507300_luag186-B5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ophtha.2024.01.023","article-title":"Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith","year":"2024","journal-title":"Ophthalmology"},{"issue":"4","key":"2026071221004507300_luag186-B6","first-page":"148","article-title":"A novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease","volume":"8","author":"Shah","year":"2022","journal-title":"AACE Clin Case Rep"},{"issue":"1","key":"2026071221004507300_luag186-B7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000536153","article-title":"Long-term follow-up of a case of severe hyperglycemia requiring hospitalization after third dose of teprotumumab: a case report","volume":"15","author":"Mehta","year":"2024","journal-title":"Case Rep Ophthalmol"},{"issue":"1","key":"2026071221004507300_luag186-B8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12020-023-03531-3","article-title":"A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease","volume":"83","author":"Carter","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"2026071221004507300_luag186-B9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000537872","article-title":"Severe hyperglycemia with teprotumumab for treatment of thyroid eye disease","volume":"15","author":"Cottom","year":"2024","journal-title":"Case Rep Ophthalmol"},{"issue":"4","key":"2026071221004507300_luag186-B10","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026071221004507300_luag186-B11","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"2026071221004507300_luag186-B12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1266339","article-title":"Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly","volume":"14","author":"Clemmons","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2026071221004507300_luag186-B13","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1210\/jcem.87.8.8658","article-title":"Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up","volume":"87","author":"Dimaraki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071221004507300_luag186-B14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bcp.12228","article-title":"The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy","volume":"77","author":"Ma","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2026071221004507300_luag186-B15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40262-021-01003-3","article-title":"Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease","volume":"60","author":"Xin","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"2026071221004507300_luag186-B16","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/cncr.28728","article-title":"A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research through Collaboration study","volume":"120","author":"Pappo","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"2026071221004507300_luag186-B17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","article-title":"Teprotumumab-related hyperglycemia","volume":"108","author":"Amarikwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026071221004507300_luag186-B18","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","article-title":"The adverse effects profile of teprotumumab","volume":"108","author":"Stan","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/8\/luag186\/68762018\/luag186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/8\/luag186\/68762018\/luag186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:03:13Z","timestamp":1783904593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag186\/8732978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag186","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"luag186"}}